Trials / Completed
CompletedNCT02156895
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
POST MARKETING SURVEILLANCE STUDY TO OBSERVE SAFETY AND EFFICACY OF INLYTA (REGISTERED)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 111 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.
Detailed description
Investigators can choose any patient who is within the scope of I/E criteria
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axitinib | based on Axitinib approval |
Timeline
- Start date
- 2018-07-17
- Primary completion
- 2021-04-21
- Completion
- 2021-08-06
- First posted
- 2014-06-05
- Last updated
- 2024-03-08
- Results posted
- 2024-03-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02156895. Inclusion in this directory is not an endorsement.